Primary tabs

Nanotechnology-Based Contraception

David Clapham of Boston Children's Hospital in the U.S. will develop and test a nanoparticle contraceptive that releases sperm tail inhibitors in response to vaginal pH changes or exposure to prostatic fluid. The nanoparticles could be incorporated into a vaginal gel to block sperm motility required for fertilization. This project's Phase I research culminated in the development of mesoporous silica nanoparticles that contain sperm inhibitors. In Phase II, Clapham will refine the efficacy and stability of the nanoparticles, conduct animal model tests, and collect data necessary to file for a new drug application.

Grant ID
OPP1025183
Show on Hub
On
Show on Spoke
On
Follow-on Funding
On
Lead Funding Organization
Principal Investigator
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
100000.00
Funding Currency
USD
Funding Amount (in USD)
100000.00
Project Type
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
100000.00
Co-Funded
False